Skip to main content
U.S. flag

An official website of the United States government

NIH Alzheimer’s Research Summit 2021: Save the Dates!

Dr. Richard Hodes
Richard J. HODES,
Director,
Office of the Director (OD)
.
Eliezer Masliah
Eliezer MASLIAH,
Director,
Division of Neuroscience (DN)
.

Mobilized by the ambitious national goal to effectively treat or prevent Alzheimer’s disease by 2025, funding and progress in research have expanded dramatically in the nine years since the first NIH Alzheimer’s Research Summit. We’ll convene again April 19-22 for the 2021 NIH Alzheimer’s Research Summit: Path to Precision Medicine for Treatment and Prevention.

The Alzheimer’s Research Summits are key strategic planning meetings that bring together a multi-stakeholder community including government, industry, academia, private foundation, and patient advocacy groups. The previous summits held in 2012, 2015, and 2018 identified critical gaps and opportunities that served as the basis for developing research milestones. The milestones detail the steps and success criteria for the NIH and other stakeholders toward the development of effective treatment and prevention for Alzheimer’s. These also span the entire research landscape and shape the development of the NIH Alzheimer's Disease Bypass Budget.

During the 2021 Alzheimer’s Research Summit, participants will share progress made toward the milestones and highlight key gaps and opportunities for the future of Alzheimer’s research. We are excited to hear from a diverse group of innovators and thought leaders working on Alzheimer’s and other complex diseases. The summit agenda is organized around seven major topics:

  • Deconstructing Disease Complexity: From Populations to Single Cells, from Genes to Multiscale Models
  • Enabling Infrastructure and Incentives to Improve Research Rigor, Reproducibility, and Translatability
  • Accelerating Therapy Development: Open Science from Targets to Trials
  • Diversifying the Therapeutic Pipeline to Develop Precision Medicines
  • Emerging Biomarkers Landscape
  • Advancing Drug Repurposing and Combination Therapy Development
  • Understanding the Impact of the Exposome on Brain Health to Advance Disease Prevention

Session topics will be complemented by focused discussions on the development of a diverse translational workforce, increasing diversity in clinical trials, and strategies to promote open science practices and accelerate the development of affordable medicines. Over the course of this four-day event, a global audience of researchers and the public will have opportunities to contribute to discussions through multiple open forum sessions.

Visit the 2021 summit website for more information. We look forward to another engaging and groundbreaking meeting. Please join us!

Comments

Submitted by Anonymous on February 24, 2021

The new NIA pay line for ADRD grant applications has not yet been published since the announcement that NIA has received $300 million increase in ADRD funding for its fiscal year 2021 budget.

Add new comment

Your e-mail address will not be posted.

Plain text

  • Allowed HTML tags: <p> <br>
  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

nia.nih.gov

An official website of the National Institutes of Health